Skye Bioscience
SKYE | NASDAQ
$1.06
-$0.03 (-2.75%)
At close: Nov 16, 2026, 4:00 PM ET
$1.08
+$0.02 (+1.82%)
After-hours:
Nov 16, 2026, 7:59 PM ET
-2.75%
(1D)No price chart data available for 1D timeframe.
Rating
26.2
-16.0 ptsFundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #896/1021 (Top 88%)
Key Statistics
Market Data
Market Cap $5.26M
1D Range
1.03 1.25
52W Range
0.69 11.20
Valuation (TTM)
PE -0.14
PB 3.87
EV/EBITDA -0.01
Valuation (NTM)
Forward PE N/A
Forward PEG 0.00
Price Target $15.00
Cash Flow
FCF Yield -581.5%
SBC Adj. FCF Yield 41131.8%
SBC Impact -7173.6%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y N/A |
N/A
Dil EPS 3Y | 5Y -5.3% |
54.3%
FCF 3Y | 5Y -0.1% |
-49.7%
Returns
ROA -742.6%
ROE -503.9%
ROIC -2818.2%
Financial Health
Net Cash
$4.81M
Current Ratio 1.36
Interest Coverage -4,388.42
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. I...
Sector Healthcare
Industry Biotechnology
Employees 2
IPO Date Jan 6, 2015
Website skyebioscience.com
Fiscal Year January - December
Latest News
No news articles available yet.
Add to Watchlist
Select watchlists to add or remove SKYE